Conventional radiography and correlated factors of enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthritis

Ebru Yılmaz; Özge Pasin; Loiane Cristina de Souza; Guilherme Torres Vilarino; Alexandro Andrade; Camila Gusmão Vicente de Carvalho; Barbara Bayeh; Fernando Henrique Carlos de Souza; Renata Miossi; Pleiades Tiharu Inaoka; Takashi Matsushita; Naoki Mugii; Samuel Katsuyuki Shinjo

doi:10.4081/reumatismo.2024.1709

Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

Search Results

##search.searchResults.foundPlural##

Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

E. Molteni, C. Pirone, F. Ceccarelli, C. Castellani, C. Alessandri, M. Di Franco, V. Riccieri, F.R. Spinelli, R. Priori, R. Scrivo, F. Conti

24-06-2024

https://doi.org/10.4081/reumatismo.2024.1608

1694

PDF: 597
Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio

08-05-2023

https://doi.org/10.4081/reumatismo.2023.1559

1798

PDF: 963
Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Bahar Özdemir Ulusoy, Özlem Karakaş, Kevser Orhan, Rezan Koçak Ulucaköy, Esra Kayacan Erdoğan, Serdar Can Güven, Orhan Küçükşahin, İsmail Doğan, Hakan Babaoğlu, Yüksel Maraş, Şükran Erten, Ahmet Omma, Berkan Armağan

26-06-2025

https://doi.org/10.4081/reumatismo.2025.1792

1671

PDF: 56
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali

17-07-2023

https://doi.org/10.4081/reumatismo.2023.1544

1184

PDF: 637
Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

19-12-2023

https://doi.org/10.4081/reumatismo.2023.1602

1942

PDF: 478
Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy

M. Tasso, N. Bertolini, E. Mostacciuolo, S. Passavanti, J.M.E. Luppino, A. Del Puente, R. Peluso, F. Santelli, R. Scarpa, L. Costa, F. Caso

29-12-2022

https://doi.org/10.4081/reumatismo.2022.1511

1992

PDF: 873
Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)

G. Carlino, M. Fornaro, L. Santo, R. Bucci, A. Semeraro, L. Quarta, F. D'Onofrio, A. Marsico, C. Zuccaro, P.C. Falappone, D. Mazzotta, F.P. Cantatore, M. Muratore, F. Iannone

24-30

01-04-2019

https://doi.org/10.4081/reumatismo.2019.1154

1667

PDF: 1177

1 - 7 of 7 items

Search

Search Results

Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy

Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)

authors

reviewers

Categories

indexing

Keywords